Network meta-analyses suggest that higher-dose semaglutide (1 mg and 2 mg weekly) and tirzepatide (a dual GIP/GLP-1 receptor agonist) demonstrate superior A1c reductions compared to other agents in the class, with mean reductions of 1.52.0% or greater from baseline
GLP-1 receptor agonists are a class of medications that mimic the glucagon-like peptide-1 hormone, enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptying to lower blood glucose levels
Patients often find that despite reaching their target weight, their physical silhouette remains hidden under folds of loose tissue
Si es necesario, su proveedor le ayudar a abordar los efectos secundarios con orientacin personalizada y opciones de tratamiento
It activates both GIP and GLP-1 receptors
Stress management through techniques like meditation or deep breathing may help, as stress can affect digestive function and symptom perception